GM Advisory Group LLC Invests $350,000 in Standard BioTools Inc. (NASDAQ:LAB)

GM Advisory Group LLC bought a new stake in shares of Standard BioTools Inc. (NASDAQ:LAB) during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The fund bought 200,000 shares of the company’s stock, valued at approximately $350,000. GM Advisory Group LLC owned approximately 0.05% of Standard BioTools at the end of the most recent quarter.

A number of other institutional investors have also recently added to or reduced their stakes in LAB. JPMorgan Chase & Co. raised its stake in shares of Standard BioTools by 7.7% during the third quarter. JPMorgan Chase & Co. now owns 139,748 shares of the company’s stock valued at $270,000 after purchasing an additional 9,995 shares during the period. HighTower Advisors LLC increased its stake in Standard BioTools by 13.0% during the 4th quarter. HighTower Advisors LLC now owns 92,791 shares of the company’s stock worth $162,000 after buying an additional 10,690 shares during the period. Wolverine Trading LLC acquired a new position in Standard BioTools in the 3rd quarter worth $27,000. Cibc World Markets Corp purchased a new position in Standard BioTools in the 4th quarter valued at about $48,000. Finally, Simon Quick Advisors LLC acquired a new stake in shares of Standard BioTools during the fourth quarter valued at about $54,000. 53.74% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Separately, KeyCorp lowered shares of Standard BioTools from an “overweight” rating to a “sector weight” rating in a research note on Thursday, February 27th.

Standard BioTools Stock Up 1.7 %

NASDAQ:LAB opened at $1.18 on Thursday. The company has a market cap of $447.20 million, a PE ratio of -1.66 and a beta of 1.62. The business’s 50 day moving average is $1.42 and its two-hundred day moving average is $1.72. Standard BioTools Inc. has a 52 week low of $0.99 and a 52 week high of $3.04.

Insider Activity

In related news, Director Casdin Partners Master Fund, L bought 4,820,959 shares of the stock in a transaction on Friday, February 28th. The shares were purchased at an average price of $1.06 per share, with a total value of $5,110,216.54. Following the purchase, the director now owns 58,846,780 shares in the company, valued at approximately $62,377,586.80. This represents a 8.92 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is available through this hyperlink. Company insiders own 53.10% of the company’s stock.

Standard BioTools Company Profile

Standard BioTools Inc, together with its subsidiaries, provides instruments, consumables, reagents, and software services for researchers and clinical laboratories in the Americas, Europe, the Middle East, Africa, and the Asia pacific. It operates through two segments: Proteomics and Genomics. The company offers analytical systems, such as CyTOF XT System, a CyTOF XT mass cytometry system performs automated high-parameter single-cell analysis using antibodies conjugated to metal isotopes; and Hyperion XTi imaging system, a spatial biology instrument.